The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|March 2, 2004
- Pharmaceutical Technology-03-02-2004
- Volume 28
- Issue 3
Pharma Industry Drives Innovation in Barrier/Isolation Design
Author(s)Kaylynn Chiarello-Ebner
The need to provide both operator and product protection while developing more efficient containment strategies has initiated a wave of innovative solutions in barrier/isolation equipment design and implementation.
Advertisement
Articles in this issue
over 22 years ago
Pharmaceutical Pricing and Healthcare Accessover 22 years ago
The Effect of Buffers on Protein Conformational Stabilityover 22 years ago
Packaging Helps Protect Temperature-Sensitive Productsover 22 years ago
Resealed Erythrocytes: A Reviewover 22 years ago
Connecting Clinical Trial Management to Pharmaceutical Manufacturingover 22 years ago
March 2003over 22 years ago
Stakes Getting Higher for ContractorsAdvertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AI Formulation: Regulators Want Data
2
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
3
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
4
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
5